Home

Loading...

Table of contents

Nasopharyngeal cancer

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of nasopharyngeal cancer are prepared by our editorial team based on guidelines from the American Society of Clinical Oncology (ASCO 2023,2018), the European Reference Network on Rare Adult Solid Cancers (EURACAN/ESMO 2023,2021), the Spanish Group for the Treatment of Head and Neck Tumors (TTCC/SEOM 2022), the Chinese Society of Clinical Oncology ...
Show more

Screening and diagnosis

Indications for screening: as per SEOM/TTCC 2022 guidelines, consider obtaining plasma EBV DNA with a primer/probe assay targeting the BamHI-W region of the EBV genome (carried out in duplicate, at least 4 weeks apart), coupled with endoscopic examination and MRI, for detecting early asymptomatic NPC in individuals at higher risk (males aged 40-62 years) in endemic areas.
B
Create free account

Diagnostic investigations

History and physical examination: as per ESMO/EURACAN 2021 guidelines, elicit medical history and perform a physical examination with cranial nerve examination in the initial evaluation and staging of patients with NPC.
E
Show 2 more

More topics in this section

  • Audiometry

  • Baseline laboratory tests

  • EBV DNA

  • Diagnostic imaging

  • Imaging for staging

Diagnostic procedures

Nasopharyngoscopy: as per ESMO/EURACAN 2021 guidelines, obtain nasopharyngoscopy for the routine staging of patients with NPC.
E

More topics in this section

  • Fine-needle aspiration

  • Tumor biopsy

  • Ancillary testing

Medical management

Management of local/locoregional disease, radiotherapy, indications
As per ASCO/CSCO 2021 guidelines:
Offer intensity-modulated radiotherapy with daily image guidance in all patients with NPC.
A
Consider offering both sequential boost and simultaneous integrated boost radiotherapy in all patients with NPC.
C

More topics in this section

  • Management of local/locoregional disease (radiotherapy, target delineation)

  • Management of local/locoregional disease (radiotherapy, dosing)

  • Management of local/locoregional disease (induction chemotherapy)

  • Management of local/locoregional disease (concurrent chemoradiotherapy)

  • Management of local/locoregional disease (adjuvant chemotherapy)

  • Management of local/locoregional disease (surgery)

  • Management of metastatic disease

  • Management of persistent/recurrent disease

Follow-up and surveillance

Serial clinical assessment: as per SEOM/TTCC 2022 guidelines, perform periodic examinations (every 3 months in the first year, every 6 months in the second and third year, and annually thereafter for the first 5 years) of the nasopharynx (with fiberoptic endoscopy), neck, and cranial nerve function, and assess systemic complaints to identify distant metastasis.
B

More topics in this section

  • Serial imaging assessment

  • Serial laboratory assessment

  • Surveillance for other cancers

  • Survivorship and rehabilitation (lifestyle modifications)

  • Survivorship and rehabilitation (neuromuscular complications)

  • Survivorship and rehabilitation (neurosensory complications)

  • Survivorship and rehabilitation (speech disturbance)

  • Survivorship and rehabilitation (oral and dental care)

  • Survivorship and rehabilitation (gastroesophageal complications)

  • Survivorship and rehabilitation (thyroid dysfunction)

  • Survivorship and rehabilitation (lymphedema)

  • Survivorship and rehabilitation (fatigue)

  • Survivorship and rehabilitation (sleep disorders)

  • Survivorship and rehabilitation (psychosocial distress)